52047-13-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2,6-dichloro-5-nitropyrimidine-4-carboxylate is used as a key intermediate in the synthesis of pyrimidine derivatives, which are being studied for their potential therapeutic applications. These derivatives have shown promise in the treatment of various diseases, including cancer, viral infections, and bacterial infections.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 2,6-dichloro-5-nitropyrimidine-4-carboxylate is utilized as a building block for the development of new compounds with pesticidal properties, contributing to the enhancement of crop protection strategies.
Used in Organic Synthesis:
Methyl 2,6-dichloro-5-nitropyrimidine-4-carboxylate is employed as a valuable reagent in organic synthesis due to its strong electron-withdrawing properties. This characteristic makes it useful in various chemical reactions, facilitating the synthesis of a wide range of organic compounds.
Used in Research and Development:
Methyl 2,6-dichloro-5-nitropyriMidine-4-carboxylate is also used in research and development settings for the exploration of new chemical entities and the study of their biological activities, further expanding the understanding of pyrimidine derivatives and their potential applications in medicine and other fields.

Upstream product

• 6311-73-5 methyl 5-nitroorotate 
• 6311-73-5 methyl 2,6-dihydroxy-5-nitropyrimidine-4-carboxylate 
• 17687-24-0 2,6-dihydroxy-5-nitropyrimidine-4-carboxylic acid 
• 65-86-1 2,4-dihydroxypyrimidine-6-carboxylic acid 

Downstream Products

• 766557-54-4 2-chloro-6-(4-methoxy-benzylamino)-5-nitro-pyrimidine-4-carboxylic acid methyl ester 
• 1022157-34-1 methyl 2-chloro-5-nitro-6-(phenylamino)pyrimidine-4-carboxylate 
• 1022158-71-9 6-(1-benzenesulfonyl-1H-indol-4-ylamino)-2-chloro-5-nitro-pyrimidine-4-carboxylic acid methyl ester 
• 502184-51-2 methyl 5-amino-2,6-dichloropyrimidine-4-carboxylate 
• 849703-65-7 6-(4-methoxy-benzylamino)-5-nitro-2-thiophen-2-yl-pyrimidine-4-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Pyrimidine fused ring derivatives and application thereof in medicine

The invention relates to compounds shown in a general formula (I) or stereoisomers, deuterated compounds, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or co-crystal of the compounds, an intermediate and a preparation method of the compounds, and application of the compounds in preparation of drugs for treating diseases related to activity or expression quantity of KRas-G12C.

INHIBITORS OF KRAS G12C MUTANT PROTEINS

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I), or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein B, W, X, Y, R1, R2a, R2b, R3a, R3b, R4a, R4b, G1, G2, m1, m2, L1, L2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

CARBAZOLE AND CARBOLINE KINASE INHIBITORS

The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit tyrosine kinase activity of Jak2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

KINASE INHIBITORS

Disclosed are protein kinase inhibitors of Formula Ia and Ib, compositions comprising such inhibitors, and methods of use, thereof. More particularly, these compounds and compositions are inhibitors of Aurora-A (Aurora-2) and Aurora-B (Aurora-1) protein k

Effect of a-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines

Several A-ring-modified analogues of the DNA-binding antitumor agent DC- 81 (5) have been synthesized in order to study structure- reactivity/cytotoxicity relationships. For two molecules (23 and 30) the modifications required the addition of a fourth rin